SCHEMBL15514768

SCHEMBL15514768

CC(C)(C=O)N1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9707183 0.94 CYP2B6 (0.32)
SCHEMBL19520207 0.92 CYP2B6 (0.35)
SCHEMBL13860177 0.92 CYP2B6 (0.35)
SCHEMBL15515320 0.81
SCHEMBL20416441 0.80 SMN1; SMN2 (0.32)
SCHEMBL1266718 0.77 SMN1; SMN2 (0.35)
SCHEMBL20399278 0.74 CHRM3 (0.30)
SCHEMBL15515285 0.74 ALDH1A1 (0.40)
SCHEMBL15515185 0.74 HSD11B1 (0.34)
SCHEMBL18345253 0.72 CYP1A2 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181567-B9 PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2025-09-24 EP disclosed
US-20240174676-A1 Pyrazolopyrimidine compounds as kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-05-30 US disclosed
CN-110483521-B Reversible covalent Bruton's tyrosine kinase inhibitor, pharmaceutical composition and application thereof 杭州和正医药有限公司 2022-06-07 CN disclosed
US-20220073522-A1 Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2022-03-10 US disclosed
US-11040980-B2 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2021-06-22 US disclosed
US-20200190092-A1 SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2020-06-18 US disclosed
EP-3181567-B1 PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2019-03-20 EP disclosed
US-20180327413-A1 SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2018-11-15 US disclosed
US-9994576-B2 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2018-06-12 US disclosed
EP-3181567-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PRINCIPIA BIOPHARMA, INC. (US) 2017-06-21 EP disclosed
US-20160251358-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2016-09-01 US disclosed
US-9266895-B2 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2016-02-23 US disclosed
EP-2892900-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS Principia Biopharma Inc. (US) 2015-07-15 EP disclosed
US-20150094295-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. 2015-04-02 US disclosed
US-8940744-B2 Pyrazolopyrimidine compounds as kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2015-01-27 US disclosed
US-20140364410-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. 2014-12-11 US disclosed
WO-2014039899-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2014-03-13 WO disclosed